455 related articles for article (PubMed ID: 27653507)
1. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
2. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
4. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission.
Daneshpazhooh M; Zafarmand Sedigh V; Balighi K; Hosseini SH; Ramezani A; Kalantari MS; Ghandi N; Ghiasi M; Nikoo A; Chams-Davatchi C
J Am Acad Dermatol; 2016 Jun; 74(6):1160-5. PubMed ID: 26896293
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
Reguiai Z; Tabary T; Maizières M; Bernard P
J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
8. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
Greenblatt DT; Benton EC; Groves RW; Setterfield JF
Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
10. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
Russo I; Miotto S; Saponeri A; Alaibac M
Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
[No Abstract] [Full Text] [Related]
11. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
12. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab.
Albers LN; Liu Y; Bo N; Swerlick RA; Feldman RJ
J Am Acad Dermatol; 2017 Dec; 77(6):1074-1082. PubMed ID: 28927663
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
[TBL] [Abstract][Full Text] [Related]
14. The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris.
Sinistro A; Calabresi V; Lupi F; Sera F; Frezzolini A; Ruffelli M; De Pità O; Camaioni D; Cianchini G; Di Zenzo G
Eur J Dermatol; 2015; 25(6):578-85. PubMed ID: 26552329
[TBL] [Abstract][Full Text] [Related]
15. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
16. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
17. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
19. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
Brown AE; Motaparthi K; Hsu S
Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
[TBL] [Abstract][Full Text] [Related]
20. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
